Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“Follow MedCity News if you want to know who is doing what in healthcare innovation - and whether it's working or not.”

Chris Seper, CEO & Founder, MedCityNews.com


Sign up for our daily newsletter


Skin cancer treatment device startup raises $2.4M for alternative to surgery

10:53 am by | 0 Comments

A noninvasive device used to treat nonmelanoma skin cancers with radiation is getting a $2.4 million boost from investors as it makes its way into more oncology centers and dermatology offices across the world.

In a recent U.S. Securities and Exchange Commission filing, Sensus Healthcare LLC reported raising $2.4 million from 19 investors. The company’s media representative couldn’t be reached for more details.

Sensus markets a superficial radiation therapy (SRT) system to treat basal cell and squamous cell carcinomas, the most common forms of skin cancer. The SRT-100 delivers targeted, low-energy radiotherapy no deeper than the thickness of the skin.

Advertisement

Traditionally, to treat nonmelanoma cancers, a procedure called Mohs surgery is performed, where the physician removes the tumor with a thin layer of tissue around it. Sensus says SRT doesn’t require anesthesia, is painless and avoids tissue damage and scarring, which results in a shorter healing time. Unlike a surgical procedure, multiple treatments are required, although each one takes only a few minutes.

Sensus was formed in 2010 in Boca Raton, Florida and acquired SRT-100 from Topex Inc. later that year. The device was featured on the show “The Doctors” in early 2012 and saw its 100th sale in September. It’s cleared for sale in the U.S., EU, Canada and China.

The Skin Cancer Foundation estimates that 2.8 million new cases of basal cell carcinoma are diagnosed each year in the U.S. Although surgery is the standard, patients who aren’t well-suited for surgery may use cryotherapy, laser surgery or topical drug treatments. Galena Biopharma, Spectrum Pharmaceuticals and Exelixis are among those developing new drug treatments.

 [Screen cap from Sensus Healthcare]

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Deanna Pogorelc

By Deanna Pogorelc MedCity News

Deanna Pogorelc is a Cleveland-based reporter who writes obsessively about life science startups across the country, looking to technology transfer offices, startup incubators and investment funds to see what’s next in healthcare. She has a bachelor’s degree in journalism from Ball State University and previously covered business and education for a northeast Indiana newspaper.
More posts by Author

0 comments